Stephens Investment Management Group LLC raised its stake in DexCom, Inc. (NASDAQ:DXCM) by 40.1% in the 4th quarter, Holdings Channel reports. The firm owned 269,511 shares of the medical device company’s stock after acquiring an additional 77,187 shares during the period. Stephens Investment Management Group LLC’s holdings in DexCom were worth $15,467,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. The Manufacturers Life Insurance Company lifted its position in DexCom by 12.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock valued at $238,000 after purchasing an additional 354 shares during the last quarter. Advisor Group Inc. raised its holdings in shares of DexCom by 104.9% during the second quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock valued at $119,000 after acquiring an additional 837 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of DexCom by 0.9% during the third quarter. Dimensional Fund Advisors LP now owns 127,769 shares of the medical device company’s stock valued at $6,247,000 after acquiring an additional 1,095 shares in the last quarter. Stifel Financial Corp raised its holdings in shares of DexCom by 15.2% during the third quarter. Stifel Financial Corp now owns 8,567 shares of the medical device company’s stock valued at $422,000 after acquiring an additional 1,129 shares in the last quarter. Finally, OLD National Bancorp IN raised its holdings in shares of DexCom by 13.2% during the third quarter. OLD National Bancorp IN now owns 9,966 shares of the medical device company’s stock valued at $488,000 after acquiring an additional 1,163 shares in the last quarter.

In other news, insider Terrance H. Gregg sold 10,000 shares of the stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $56.86, for a total value of $568,600.00. Following the sale, the insider now directly owns 484,559 shares of the company’s stock, valued at $27,552,024.74. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Richard Doubleday sold 1,635 shares of the stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $54.67, for a total value of $89,385.45. Following the completion of the sale, the executive vice president now directly owns 65,049 shares in the company, valued at $3,556,228.83. The disclosure for this sale can be found here. Over the last three months, insiders sold 48,140 shares of company stock worth $2,743,281. Insiders own 1.70% of the company’s stock.

A number of equities analysts recently commented on DXCM shares. BidaskClub downgraded DexCom from a “strong-buy” rating to a “buy” rating in a report on Friday, December 22nd. Jefferies Group upped their target price on DexCom from $58.00 to $70.00 and gave the company a “buy” rating in a report on Friday, December 22nd. TheStreet downgraded DexCom from a “c-” rating to a “d+” rating in a report on Wednesday, October 25th. Barclays decreased their target price on DexCom from $60.00 to $57.00 and set an “equal weight” rating for the company in a report on Thursday, November 2nd. Finally, Northland Securities restated a “hold” rating and set a $50.00 target price on shares of DexCom in a report on Thursday, November 2nd. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have issued a buy rating to the stock. DexCom presently has an average rating of “Hold” and a consensus target price of $68.50.

Shares of DexCom, Inc. (NASDAQ:DXCM) opened at $54.84 on Thursday. DexCom, Inc. has a 12 month low of $42.62 and a 12 month high of $86.32. The company has a market capitalization of $4,832.68, a price-to-earnings ratio of -96.21 and a beta of 0.21. The company has a quick ratio of 5.50, a current ratio of 5.86 and a debt-to-equity ratio of 0.84.

COPYRIGHT VIOLATION WARNING: “Stephens Investment Management Group LLC Buys 77,187 Shares of DexCom, Inc. (DXCM)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2018/02/08/stephens-investment-management-group-llc-buys-77187-shares-of-dexcom-inc-dxcm.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.